We use cookies to collect information, and enable our website to work properly. Please tell us whether you accept cookies by clicking the button below. If you decide not to accept cookies, our site may not work as expected and some information may not be available.
Click here for more information on cookies, including how to remove them.
GenQA supports truly global participation by accepting EQA submissions in English, French, German, Italian, Polish, Portuguese, and Spanish - breaking language barriers to ensure accessible, high-quality genomic assessment worldwide.
GenQA provides EQAs for individual genes and multi-gene NGS panel testing to reflect the variable approach to pharmacogenomic testing across the globe. These EQAs are available to all laboratories providing clinical testing for pharmacogenomic variants/alleles using any appropriate technology.
In conjunction with our expert advisors, we provide assessment of genotyping for all EQAs in addition to clinical interpretation where applicable.
Summary information:
Assess your testing and reporting of pharmacogenomic variants/alleles.
Cases based on real-world clinical scenarios, using validated samples.
6 weeks to test samples and submit results
Submitted results are assessed by an expert scientific panel.
Each participant receives an Individual Laboratory Report (ILR) and EQA summary report detailing general findings, a summary of methodologies used, common errors and benchmarking against other laboratories worldwide.
Offers:
Enrol in 3 non-pilot Pharmacogenomics EQA: Add Pharmacogenomics Panel EQA (PGXP) for FREE!
Molecular testing of variants in common pharmacogenetics genes.
Updated: The content and format of this EQA is under review, pending feedback from the 2025 EQA results. Please contact info@genqa.org for more information. Additional genes will be added to the panel for 2026.
NEWSLETTER SIGN UP